Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
98 hedge funds and large institutions have $207M invested in Adamas Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 41 increasing their positions, 26 reducing their positions, and 41 closing their positions.
435% more call options, than puts
Call options by funds: $2.47M | Put options by funds: $462K
58% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 26
22% less funds holding
Funds holding: 125 → 98 (-27)
60% less capital invested
Capital invested by funds: $514M → $207M (-$307M)
63% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 41
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$16.7M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$12M |
| 3 |
AC
Armistice Capital
New York
|
+$8.56M |
| 4 |
Morgan Stanley
New York
|
+$6.58M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$4.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$18.8M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$18.2M |
| 3 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
-$10.2M |
| 4 |
PA
Perceptive Advisors
New York
|
-$8.45M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$6.92M |
ADMS Hedge Fund Activity: Q4 2018 in Review
98 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q4 2018, worth a combined $207M — down 60% from $514M a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of ADMS and 15 opened new positions — a net loss of 26 holders — while 26 trimmed existing stakes and 41 added.
The largest buyer was Broadfin Capital, adding an estimated $16.7M. The largest seller was State Street, cutting an estimated $18.8M.
- 98 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q4 2018, down from 125 in Q3 2018.
- Funds reported $207M of Adamas Pharmaceuticals stock for Q4 2018, down 60% quarter-over-quarter.
- 15 funds opened new Adamas Pharmaceuticals positions in Q4 2018 and 41 closed out, a net change of -26 holders.
- The largest Adamas Pharmaceuticals buyer in Q4 2018 was Broadfin Capital, an estimated $16.7M added.
- The largest Adamas Pharmaceuticals seller in Q4 2018 was State Street, an estimated $18.8M sold.
Based on aggregated 13F filings for Q4 2018.